Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tvardi Therapeutics (TVRD) Net Margin: 2013-2017

Historic Net Margin for Tvardi Therapeutics (TVRD) over the last 2 years, with Mar 2017 value amounting to -2,437.32%.

  • Tvardi Therapeutics' Net Margin rose 15030554.00% to -2,437.32% in Q1 2017 from the same period last year, while for Mar 2017 it was -2,001.54%, marking a year-over-year decrease of 119595.00%. This contributed to the annual value of -66,604.65% for FY2016, which is 6595543.00% down from last year.
  • Latest data reveals that Tvardi Therapeutics reported Net Margin of -2,437.32% as of Q1 2017, which was up 85.27% from -16,550.63% recorded in Q2 2016.
  • Tvardi Therapeutics' Net Margin's 5-year high stood at -196.19% during Q3 2015, with a 5-year trough of -152,742.86% in Q1 2016.
  • Over the past 3 years, Tvardi Therapeutics' median Net Margin value was -1,698.11% (recorded in 2015), while the average stood at -28,922.71%.
  • As far as peak fluctuations go, Tvardi Therapeutics' Net Margin crashed by 15,178,396bps in 2016, and later skyrocketed by 15,030,554bps in 2017.
  • Quarterly analysis of 5 years shows Tvardi Therapeutics' Net Margin stood at -215.11% in 2013, then tumbled by 24,135bps to -456.46% in 2014, then soared by 38,559bps to -196.19% in 2015, then tumbled by 1,590,029bps to -16,550.63% in 2016, then spiked by 15,030,554bps to -2,437.32% in 2017.
  • Its Net Margin stands at -2,437.32% for Q1 2017, versus -16,550.63% for Q2 2016 and -152,742.86% for Q1 2016.